Zeprumetostat

泽美妥司他

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameZeprumetostat
Drug Alias Name艾瑞璟SHR2554SHR-2554EBI 2554
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsMature T- and NK-cell lymphomasGastroesophageal Junction NeoplasmsSolid tumours +[23] 
Global Approved IndicationsLymphoma, T-Cell, Peripheral
Approved Indications in ChinaLymphoma, T-Cell, Peripheral
Original Approved Country/TerritoryMainland China
Original Approved Date2025/08/26
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPla General HospitalThe Third Affiliated Hospital Of Beijing UniversityTreeline Biosciences Inc +[9] 
Inactive Companies +[1]  N/A
Active IndicationsMature T- and NK-cell lymphomasGastroesophageal Junction NeoplasmsBehavior Therapy +[20] 
Inactive IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A